Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab)

Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications

Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access to biologic medicines in the U.S. market

Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1